NOVN — Novartis Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Novartis, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	43,974	43,375	46,660	51,722	56,330
Cost of Revenue
Gross Profit	32,583	32,164	34,640	38,907	42,710
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	33,982	35,566	37,085	37,409	38,866
Operating Profit	9,992	7,809	9,575	14,313	17,464
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	24,530	7,177	9,123	13,640	16,352
Provision for Income Taxes
Net Income After Taxes	22,905	6,049	8,572	11,939	13,967
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	24,021	6,955	14,850	11,941	13,984
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	24,021	6,955	14,850	11,941	13,984
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	10.6	3.59	5.45	6.58	7.72
Dividends per Share